LY2874455

Catalog No.S7057 Batch:S705701

Print

Technical Data

Formula

C21H19Cl2N5O2
Molecular Weight 444.31 CAS No. 1254473-64-7
Solubility (25°C)* In vitro DMSO 88 mg/mL (198.05 mM)
Ethanol 88 mg/mL (198.05 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description LY2874455 is a pan-FGFR inhibitor with IC50 of 2.8 nM, 2.6 nM, 6.4 nM, and 6 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively, and also inhibits VEGFR2 activity with IC50 of 7 nM. Phase 1.
Targets
FGFR2 [1]
(Cell-free assay)		 FGFR1 [1]
(Cell-free assay)		 FGFR4 [1]
(Cell-free assay)		 FGFR3 [1]
(Cell-free assay)		 VEGFR2 [1]
(Cell-free assay)
2.6 nM 2.8 nM 6 nM 6.4 nM 7 nM
In vitro In RT-112 cells, HUVECs, KATO-III cells, and SNU-16 cells, LY2874455 inhibits FGF/FGFR-mediated signaling activities. LY2874455 shows FGFR-dependent antiproliferative effects in KMS-11, OPM-2, SNU-16 and KATO-III cells. [1]
In vivo LY2874455 exhibits a potent inhibition of FGF-induced Erk phosphorylation in the heart tissues of mice with TED50 and TED90 values of 1.3 and 3.2 mg/kg, respectively. In mice bearing RT-112, OPM-2 (DSMZ), SNU-16, or NCI-H460 xenograft, LY2874455 (3 mg/kg p.o.) results in dose-dependent inhibition of the tumor growth. [1]

Protocol (from reference)

Kinase Assay:

[1]
  • Biochemical filter-binding assays for detection of FGFR phosphorylation activities

    Reaction mixtures contains 8 mM Tris-HCl (pH 7.5), 10 mmol/L HEPES, 5 mM dithiothreitol, 10 μM ATP, 0.5 μCi 33P-ATP, 10 mM MnCl2, 150 mM NaCl, 0.01% Triton X-100, 4% dimethyl sulfoxide, 0.05 mg/mL poly(Glu:Tyr) (4:1, average molecular weight of 20–50 kDa), and 7.5, 7.5, and 16 ng of FGFR1, FGFR3, and FGFR4, respectively, and are incubated at room temperature for 30 minutes followed by termination with 10% H3PO4. The reaction mixtures are transferred to 96-well MAFB filter plates that are washed 3 times with 0.5% H3PO4. After air-drying, the plates are read with a Trilux reader.
Cell Assay:

[1]
  • Cell lines

    KMS-11, OPM-2, L-363, U266, SNU-16, KATO-III, NUGC-3 and SH-10-TC cells

  • Concentrations

    ~1 μM

  • Incubation Time

    72 hours

  • Method

    Cells (2,000 per well) are first grown in RPMI for 6 hours and treated with LY2874455 at 37 ℃ for 3 days. The cells are stained at 37℃ for 4 hours and then solubilized at 37℃ for 1 hour. Finally, the plate is read at 570 nm using a plate reader (Spectra Max Gemini XS).
Animal Study:

[1]
  • Animal Models

    Mice bearing RT-112, OPM-2 (DSMZ), SNU-16, or NCI-H460 xenograft

  • Dosages

    3 mg/kg

  • Administration

    p.o.

Customer Product Validation

Data from [Data independently produced by , , PLoS One. 2016, 11(9): e0162491]

Selleck's LY2874455 has been cited by 16 publications

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer [ Cancer Discov, 2023, 13(9):1998-2011] PubMed: 37377403
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer [ Cancer Discov, 2023, 13(9):1998-2011] PubMed: 37377403
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer [ Cancer Discov, 2023, 13(9):1998-2011] PubMed: 37377403
Recapitulating early human development with 8C-like cells [ Cell Rep, 2022, 39(12):110994] PubMed: 35732112
Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma [ Br J Cancer, 2022, 10.1038/s41416-022-01973-6] PubMed: 36097178
Targeting PEA3 transcription factors to mitigate small cell lung cancer progression [ Oncogene, 2022, 10.1038/s41388-022-02558-6] PubMed: 36509998
Sensitization of osteosarcoma to irradiation by targeting nuclear FGFR1 [ Biochem Biophys Res Commun, 2022, 621:101-108] PubMed: 35820279
The cytokine FAM3B/PANDER is an FGFR ligand that promotes posterior development in Xenopus [ Proc Natl Acad Sci U S A, 2021, 118(20)e2100342118] PubMed: 33975953
Depletion of CLK2 sensitizes glioma stem-like cells to PI3K/mTOR and FGFR inhibitors [ Am J Cancer Res, 2020, 10(11):3765-3783] PubMed: 33294266
Chemical genomics reveals inhibition of breast cancer lung metastasis by Ponatinib via c-Jun. [ Protein Cell, 2019, 10(3):161-177] PubMed: 29667003

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.